Neurosterix
PrivateLast Round
Series B
Nov 11, 2026
Est. Valuation
$218.82M
Total Funding Raised
$170M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Neurosterix operates in Healthcare & Life Sciences and is based in Geneva. Its latest recorded funding round was a Series B round in November 2026.
Neurosterix is a biopharmaceutical company that develops allosteric modulator therapeutics for the treatment of neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neurosterix Comparables
Compare Neurosterix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Noema Pharma | 82% | |
| NeuShen Therapeutics | 81% | |
| MapLight Therapeutics | 81% |
For institutional investors. Book with your work email.
Neurosterix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 11, 2026 | ||||
| Series A | Apr 3, 2024 |
For institutional investors. Book with your work email.
Neurosterix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series B |
| GV | Series B |
| Perceptive Advisors | Series B, Series A |
| Xontogeny | Series A |
| Ikarian Capital | Series B |
| Acorn Bioventures | Series B, Series A |
| Dellora Investments | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 11, 2026
$105M round led by RTW Investments.
- Aug 20, 2026
Monthly visitors increased 43% MoM, reaching 1K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresNov 12, 2026
Neurosterix appoints Stephen Brannan, M.D., as Chair of the Clinical Advisory Board in conjunction with its financing on Nov 12th '26.
- hiresNov 12, 2026
Neurosterix appoints Andrew Miller, Ph.D., as Executive Chair of the Board of Directors in conjunction with its financing on Nov 12th '26.
- hiresNov 12, 2026
Neurosterix announces Edmund Harrigan, M.D., as an independent director in conjunction with its financing.
- receives_financingNov 11, 2026
Neurosterix closes a $105M Series B financing from a syndicate of leading life science investors in Switzerland on Nov 11th '26, with proceeds supporting planned Phase 2 development of NTX-253 and its broader neuropsychiatric pipeline.
- is_developingSep 27, 2026
Neurosterix continues to progress M4 PAM candidate, NTX-253, an M4 positive allosteric modulator with potential in schizophrenia, through Phase 1 clinical development in Switzerland and is on track to complete the study in Q4 '26.
For institutional investors. Book with your work email.
Neurosterix Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neurosterix's valuation, stock price, and market status.
Is Neurosterix a public or private company?
Neurosterix is a private company.
What is the current stock price of Neurosterix?
Neurosterix is a private company, so its shares have no public market price. Caplight tracks Neurosterix's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neurosterix worth (valuation)?
Neurosterix's valuation is estimated at $218.8M based on funding round data.
Can I buy Neurosterix stock?
Neurosterix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neurosterix's last funding round?
Neurosterix's most recent funding round was Series B on November 11, 2026.
Who are the main investors in Neurosterix?
Key investors in Neurosterix include Perceptive Advisors, Xontogeny, RTW Investments.
Will Neurosterix IPO soon?
No public IPO plans have been announced for Neurosterix.
How can I track Neurosterix secondary market activity?
Caplight tracks bids, offers, and trades in Neurosterix's shares on secondary markets.